HDL in innate and adaptive immunity

Cardiovascular Research

Volumn 103, Issue 3, 2014, Pages 372-383

  Catapano, Alberico Luigi ^a,b   Pirillo, Angela ^b,c   Bonacina, Fabrizia ^a   Norata, Giuseppe Danilo ^a,c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c Center for the Study of Atherosclerosis Ospedale Bassiniz   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

HDL; Immunity; Lipid rafts; Macrophages

Indexed keywords

HIGH DENSITY LIPOPROTEIN; AUTACOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADAPTIVE IMMUNITY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BACTERIAL OUTER MEMBRANE; CELL ADHESION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOTOXEMIA; HOST RESISTANCE; HUMAN; HYPOALPHALIPOPROTEINEMIA; IMMUNOMODULATION; INNATE IMMUNITY; LEUKOCYTOSIS; LIPID RAFT; MACROPHAGE; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ANIMAL; BLOOD; CHEMISTRY; GENETICS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; PARASITIC DISEASES; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; ENDOTOXEMIA; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; PARASITIC DISEASES; SIGNAL TRANSDUCTION;

EID: 84905569572     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu150     Document Type: Review

References (176)

1. Bruce IN. Not only..but also: Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:1492-1502
2. Bruce IN. Atherogenesis and autoimmune disease: The model of lupus. Lupus 2005;14: 687-690
3. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93: 513-519
4. De Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and lupus dyslipoproteinemia. Autoimmun Rev 2008;7:246-250
5. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-3347
6. Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012;220:11-21
7. Norata GD, Pirillo A, Catapano AL. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol 2011;22:410-416
8. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 1999;40:245-252
9. Guo L, Ai J, Zheng Z, Howatt DA, Daugherty A, Huang B, Li XA. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem 2013;288: 17947-17953
10. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979;64:1516-1524
11. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981;67:827-837
12. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, Remaley AT, Csako G, Eggerman TL, Patterson AP. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 2003;278: 22771-22780
13. Guo L, Zheng Z, Ai J, Howatt DA, Mittelstadt PR, Thacker S, Daugherty A, Ashwell JD, Remaley AT, Li XA. Scavenger receptor BI and high-density lipoprotein regulate thymocyte apoptosis in sepsis. Arterioscler Thromb Vasc Biol 2014;34:966-975
14. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007;33:25-35
15. Birjmohun RS, van Leuven SI, Levels JH, van t Veer C, Kuivenhoven JA, Meijers JC, Levi M, Kastelein JJ, van Der Poll T, Stroes ES. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007;27:1153-1158
16. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31: 1359-1366
17. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, Modlin RL. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008;118:2917-2928
18. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993;90: 12040-12044
19. Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995;126: 548-558
20. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van Der Poll T, ten Cate JW, van Deventer SJ. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608
21. Quezado ZM, Natanson C, Banks SM, Alling DW, Koev CA, Danner RL, Elin RJ, Hosseini JM, Parker TS, Levine DM, Rubin AL, Hoffman WD. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock. J Pharmacol Exp Ther 1995;272:604-611
22. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, OConnor PM, Malloy MJ, Kane JP. Apolipoprotein L, anewhumanhigh density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 1997;272:25576-25582
23. Vanhollebeke B, Pays E. The trypanolytic factor of human serum: Many ways to enter the parasite, a single way to kill. Mol Microbiol 2010;76:806-814
24. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005;309:469-472
25. Yvan-Charvet L,Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010;30: 139-143
26. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007;117:3900-3908
27. Out R, JessupW, Le GoffW, HoekstraM, Gelissen IC, Zhao Y, Kritharides L, Chimini G, Kuiper J, Chapman MJ, Huby T, Van Berkel TJ, Van Eck M. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2008; 102:113-120
28. Yvan-Charvet L,Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, Ishibashi M, Li R, Wang N, Tall AR. Increased inflammatory gene expression in ABC transporterdeficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008;118: 1837-1847
29. Out R, HoekstraM, Habets K, Meurs I, deWaard V, Hildebrand RB,Wang Y, Chimini G, Kuiper J, Van Berkel TJ, Van Eck M. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008; 28:258-264
30. Hansson GK, Bjorkholm M. Medicine. Tackling two diseases with HDL. Science 2010; 328:1641-1642
31. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S,Welch CL,Wang N, Randolph GJ, Snoeck HW, Tall AR. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010;328:1689-1693
32. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009;29:843-849
33. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, Bhat S, Gibbs DP Jr, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr2/2, ApoA-I2/2 mice. J Biol Chem 2010;285:36158-36169
34. Feng H, Guo L,Wang D, Gao H, Hou G, Zheng Z, Ai J, Foreman O, Daugherty A, Li XA. Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler Thromb Vasc Biol 2011;31:2543-2551
35. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role inHDLmetabolism. Proc Natl Acad Sci USA 1997; 94:12610-12615
36. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D, Kruijt JK, Sattler W, Tietge UJ, Ninio E, Van Berkel TJ, Pratico D. Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol 2007;27: 2413-2419
37. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989;30: 39-49
38. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS. HDL content and composition in acute phase response in three species: Triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 1996;37:2662-2674
39. Lowell CA, Stearman RS, Morrow JF. Transcriptional regulation of serum amyloid A gene expression. J Biol Chem 1986;261:8453-8461
40. Navarro MA, Carpintero R, Acin S, Arbones-Mainar JM, Calleja L, Carnicer R, Surra JC, Guzman-Garcia MA, Gonzalez-Ramon N, Iturralde M, Lampreave F, Pineiro A, Osada J. Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 2005;31:52-63
41. Tape C, Kisilevsky R. Apolipoprotein A-I and apolipoproteinSAAhalf-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1990;1043:295-300
42. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005;33:1688-1693
43. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res 2004;45:1169-1196
44. CoetzeeGA, StrachanAF, van derWesthuyzen DR,Hoppe HC,Jeenah MS, De Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986;261:9644-9651
45. Badellino KO,Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase is increased in vivo by inflammation in humans. Circulation 2008;117:678-685
46. De La Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012;222:390-394
47. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 1985;26:1389-1398
48. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-2767
49. Graversen JH, Castro G, Kandoussi A, Nielsen H, Christensen EI, Norden A, Moestrup SK. A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II. Lipids 2008;43:467-470
50. Feingold KR,MemonRA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139:307-315
51. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-Activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998;273:4012-4020
52. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C. In vivo regulation of plasma platelet-Activating factor acetylhydrolase during the acute phase response. Am J Physiol 1999;277:R94-103
53. Banka CL, Yuan T, De Beer MC, Kindy M, Curtiss LK, De Beer FC. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995;36: 1058-1065
54. McGillicuddy FC, De La Llera MoyaM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135-1145
55. Kumaraswamy SB, Linder A, Akesson P, Dahlback B. Decreased plasma concentrations of apolipoproteinMin sepsis and systemic inflammatory response syndromes. Crit Care 2012;16:R60
56. Feingold KR, Shigenaga JK, Chui LG, Moser A, KhovidhunkitW, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008;199: 19-26
57. Wolfrum C, Poy MN, Stoffel M. ApolipoproteinMis required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005; 11:418-422
58. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B. Endothelium-protective sphingosine-1-phosphate provided by HDL-Associated apolipoprotein M. Proc Natl Acad Sci U S A 2011;108:9613-9618
59. Nofer JR. High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis. J Clin Lipidol 2008;2:4-11
60. NorataGD,Marchesi P, Pirillo A, Uboldi P, Chiesa G, MainaV, Garlanda C, Mantovani A, Catapano AL. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008;28: 925-931
61. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005;111:2805-2811
62. Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 2012;124:116-125
63. Cederholm A, Svenungsson E, Stengel D, Fei GZ, Pockley AG, Ninio E, Frostegard J. Platelet-Activating factor-Acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004;50: 2869-2876
64. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E,Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. Proinflammatory highdensity lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-2549
65. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870-2879
66. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-539
67. IlowiteNT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-863
68. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003;48:2533-2540
69. Ammirati E, Bozzolo EP, Contri R, Baragetti A, PaliniAG, Cianflone D, Banfi M, Uboldi P, Bottoni G, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis 2014;24:751-759
70. Kontush A, De Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress andHDLparticles with attenuated antioxidative activity. Atherosclerosis 2005;182:277-285
71. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2002;22:656-661
72. Brites FD, Bonavita CD, De Geitere C, Cloes M, Delfly B, Yael MJ, Fruchart J, WikinskiRW, Castro GR. Alterations in themain steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000;152:181-192
73. Juarez-Rojas J, Medina-Urrutia A, Posadas-Sanchez R, Jorge-Galarza E, Mendoza-Perez E, Caracas-Portilla N, Cardoso-Saldana G, Munoz-Gallegos G, Posadas-Romero C. High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus 2008;17:981-987
74. Tian L, Fu M. The relationship between high density lipoprotein subclass profile and plasma lipids concentrations. Lipids Health Dis 2010;9:118
75. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM. Normalization of obesity-Associated insulin resistance through immunotherapy. Nat Med 2009;15:921-929
76. WinerDA, Winer S, Shen L,Wadia PP, Yantha J, Paltser G, Tsui H,WuP, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011;17: 610-617
77. He D, Pan B, Ren H, Zheng L. Effects of diabetic HDL on endothelial cell function. Cardiovasc Hematol Disord Drug Targets 2014; [Epub ahead of print].
78. Pan B,Ma Y, Ren H, He Y,Wang Y, Lv X, Liu D, Ji L, Yu B,Wang Y, Chen YE, Pennathur S, Smith JD, Liu G, Zheng L. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLoS One 2012; 7:e48530
79. Kruit JK, Brunham LR, Verchere CB, Hayden MR.HDLandLDLcholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010;21: 178-185
80. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, Kastelein JJ, Stroes ES, De Groot E, HommesDW. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohns disease. J Lipid Res 2007;48:2640-2646
81. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. Journal of Clinical Lipidology 2010;4:478-482
82. Norata GD, Catapano AL. HDL and adaptive immunity: A tale of lipid rafts. Atherosclerosis 2012;225:34-35
83. McDonald G, Deepak S, Miguel L, Hall CJ, Isenberg DA, Magee AI, Butters T, Jury EC. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest 2014;124:712-724
84. Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol 2007;18:608-615
85. Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011;13:207
86. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003;16:379-414
87. Bingle CD, Craven CJ. Meet the relatives: A family of BPI- and LBP-related proteins. Trends Immunol 2004;25:53-55
88. Hailman E, Albers JJ,Wolfbauer G, Tu AY, Wright SD. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem 1996;271: 12172-12178
89. Gautier T, Lagrost L. Plasma PLTP (phospholipid-transfer protein): An emerging role in reverse lipopolysaccharide transport and innate immunity. Biochem Soc Trans 2011;39: 984-988
90. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity andmRNAlevels by lipopolysaccharide and high cholesterol diet. J Biol Chem 1995;270: 17133-17138
91. Gautier T, Klein A, Deckert V, Desrumaux C, Ogier N, Sberna AL, Paul C, Le Guern N, Athias A, Montange T, Monier S, Piard F, Jiang XC, Masson D, Lagrost L. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem 2008;283:18702-18710
92. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001;42:281-290
93. Yu Y, Guo S, Feng Y, Feng L, Cui Y, Song G, Luo T, Zhang K,Wang Y, Jiang XC, Qin S. Phospholipid transfer protein deficiency decreases the content of S1P in HDL via the loss of its transfer capability. Lipids 2014;49:183-190
94. Hardardottir I, Moser AH, Fuller J, Fielding C, Feingold K, Grunfeld C. Endotoxin and cytokines decrease serum levels and extra hepatic protein andmRNA levels of cholesteryl ester transfer protein in syrian hamsters. J Clin Invest 1996;97:2585-2592
95. Masucci-Magoulas L, Moulin P, Jiang XC, Richardson H, Walsh A, Breslow JL, Tall A. Decreased cholesteryl ester transfer protein (CETP)mRNAand protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest 1995;95:1587-1594
96. Cazita PM, Barbeiro DF, Moretti AI, Quintao EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: A novel role for CETP. Shock 2008;30:590-595
97. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, Matsuo T, Carrilho AJ. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010;40:330-338
98. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071-2077
99. Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ, Jiang F. Reconstituted highdensity lipoprotein suppresses leukocyteNADPHoxidase activation by disrupting lipid rafts. Free Radic Res 2009;43:772-782
100. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-572
101. BrownDA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998;14:111-136
102. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 2011;187:1529-1535
103. Kabouridis PS, Jury EC. Lipid rafts and T-lymphocyte function: Implications for autoimmunity. FEBS Lett 2008;582:3711-3718
104. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol 2007;18: 616-626
105. Oram JF, Lawn RM, Garvin MR,Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000; 275:34508-34511
106. Wang N, Lan D, ChenW, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;101:9774-9779
107. Yin K, Chen WJ, Zhou ZG, Zhao GJ, Lv YC, OuyangXP, Yu XH, Fu Y, Jiang ZS, Tang CK. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb 2012;19:823-836
108. Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, Bochem AE, Kuivenhoven JA, Yvan-Charvet L, Tall AR. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121:4138-4149
109. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8:753-763
110. spotlight on sphingosine-1-phosphate-rich HDL. Curr Opin Lipidol 2013;24:351-356
111. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocytemacrophage activation in atherosclerosis. J Inflamm (Lond) 2011;8:9
112. Sala F, Cutuli L, Grigore L, Pirillo A, Chiesa G, Catapano AL, Norata GD. Prevalence of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. Int J Cardiol 2013;168:2886-2889
113. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, Sviridov D, Chin-Dusting JP. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein a-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 2011;31:1333-1341
114. Murphy AJ,Westerterp M, Yvan-Charvet L, Tall AR. Anti-Atherogenic mechanisms of high density lipoprotein: Effects on myeloid cells. Biochim Biophys Acta 2012;1821: 513-521
115. Liu G, Yang H. Modulation of macrophage activation and programming in immunity. J Cell Physiol 2013;228:502-512
116. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, Fisher EA. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A 2011;108:7166-7171
117. Colin S, Fanchon M, Belloy L, Bochem AE, Copin C, Derudas B, Stroes ES, Hovingh GK, Kuivenhoven JA, Dallinga-Thie GM, Staels B, Chinetti-Gbaguidi G. HDL does not influence the polarization of human monocytes toward an alternative phenotype. Int J Cardiol 2014;172:179-184
118. Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, Chaddha M, Kurundkar AR, Datta G. Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 2010;298: C1538-C1548
119. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007;219:187-203
120. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009;9:692-703
121. Suzuki M, Pritchard DK, Becker L, Hoofnagle AN, Tanimura N, Bammler TK, Beyer RP, Bumgarner R, VaisarT, De Beer MC, De Beer FC, Miyake K,OramJF, HeineckeJW. Highdensity lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010;122:1919-1927
122. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Rocken M, Lutjohann D, Wright SD, Schultze JL, Latz E. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature Immunol 2014;15:152-160
123. Whitmore MM, Iparraguirre A, Kubelka L,WeningerW, Hai T, Williams BR. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 2007;179:3622-3630
124. Zhang H, Reilly MP. Anti-inflammatory effects of high-density lipoprotein through activating transcription factor 3: Benefit beyond cholesterol transport-dependent processes. Arterioscler Thromb Vasc Biol 2014;34:e11-e12
125. Koseki M, Hirano K, Masuda D, Ikegami C, Tanaka M, Ota A, Sandoval JC, Nakagawa-Toyama Y, Sato SB, Kobayashi T, Shimada Y, Ohno-Iwashita Y, Matsuura F, Shimomura I, Yamashita S. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-Alpha secretion in Abca1-deficient macrophages. J Lipid Res 2007;48:299-306
126. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, Willingham MC, Hiltbold EM, Mishra N, Maeda N, Parks JS. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008;283:22930-22941
127. Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, Fessler MB, Parks JS. MacrophageABCA1reducesMyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res 2010;51:3196-3206
128. Cheng AM, Handa P, Tateya S, Schwartz J, Tang C, Mitra P,OramJF, Chait A, Kim F. Apolipoprotein A-I attenuates palmitate-mediated NF-kappaB activation by reducing Tolllike receptor-4 recruitment into lipid rafts. PLoS One 2012;7:e33917
129. White CR, Smythies LE, Crossman DK, Palgunachari MN, Anantharamaiah GM, Datta G. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler Thromb Vasc Biol 2012;32:2631-2639
130. Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res 2010;106:1861-1869
131. Li XA, Guo L, Asmis R, Nikolova-Karakashian M, Smart EJ. Scavenger receptor BI prevents nitric oxide-induced cytotoxicity and endotoxin-induced death. Circ Res 2006;98: E60-e65
132. Guo L, Song Z, Li M,WuQ,Wang D, Feng H, Bernard P, Daugherty A, Huang B, Li XA. Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. J Biol Chem 2009;284:19826-19834
133. Duenas AI, Aceves M, Fernandez-Pisonero I, Gomez C, Orduna A, Crespo MS, Garcia-Rodriguez C. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effectof sphingosine 1-phosphate. Cardiovasc Res 2008;79:537-544
134. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1- phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008; 102:950-958
135. Michaud J, Im DS, Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 2010;184:1475-1483
136. Ni K, ONeill HC. The role of dendritic cells in T cell activation. Immunol Cell Biol 1997; 75:223-230
137. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, Paik SG, Kim YS, Yang Y, Lim JS. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 2005; 338:1126-1136
138. Perrin-Cocon L, Diaz O,Carreras M, Dollet S, Guironnet-Paquet A, Andre P, LotteauV. High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology 2012;217:91-99
139. Eren E, Yates J,Cwynarski K, Preston S,Dong R, Germain C, Lechler R,Huby R, Ritter M, LombardiG. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol 2006;63:7-16
140. Wang SH, Yuan SG, Peng DQ, Zhao SP. HDL and ApoA-I inhibit antigen presentationmediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis 2012;225:105-114
141. Bondarenko S, Catapano AL, Norata GD. The CD1d-natural killer T cell axis in atherosclerosis. J Inn Immun 2014;6:3-12
142. Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. Int Immunol 2013;25: 615-622
143. Idzko M, Panther E, Corinti S, Morelli A, Ferrari D, Herouy Y, Dichmann S, Mockenhaupt M, Gebicke-Haerter P, Di Virgilio F, Girolomoni G, Norgauer J. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 2002; 16:625-627
144. Schaper K, Kietzmann M, Baumer W. Sphingosine-1-phosphate differently regulates the cytokine production of IL-12, IL-23 and IL-27 in activated murine bone marrow derived dendritic cells. Mol Immunol 2014;59:10-18
145. EhrensteinMR, Jury EC, Mauri C. Statins for atherosclerosis-As good as it gets?NEngl J Med 2005;352:73-75
146. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, ParsonsW, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349
147. Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 2010;11:1047-1056
148. Dykstra ML, Longnecker R, Pierce SK. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 2001;14:57-67
149. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Decreased
150. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134:97-111
151. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini AG, Norata GD. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. J Am Heart Assoc 2012;1:27-41
152. Ammirati E, Monaco C, Norata GD. Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T-cells during atherosclerosis. Circ Res 2012; 111:e48-e49; author reply e50-41
153. al-Janadi N, al-Dalaan A, al-Balla S, Raziuddin S. CD4+ T cell inducible immunoregulatory cytokine response in rheumatoid arthritis. J Rheumatol 1996;23:809-814
154. Gringhuis SI, Leow A, Papendrecht-Van Der Voort EA, Remans PH, Breedveld FC, Verweij CL. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol 2000;164:2170-2179
155. Romagnoli P, Strahan D, Pelosi M, Cantagrel A, van Meerwijk JP. A potential role for protein tyrosine kinase p56(lck) in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness. Int Immunol 2001;13:305-312
156. ScanuAM, Edelstein C. HDL: Bridging past and present with a look at the future. Faseb J 2008;22:4044-4054
157. Weigert A, Weis N, Brune B. Regulation of macrophage function by sphingosine-1- phosphate. Immunobiology 2009;214:748-760
158. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360
159. Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores Lck expression and lipid raft-Associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 2006;177:7416-7422
160. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL. Reconstituted highdensity lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995;63:253-258
161. WuBJ, Ong KL, Shrestha S, Chen K, Tabet F, Barter PJ, Rye KA. Inhibition of arthritis in the Lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins. Arterioscler Thromb Vasc Biol 2014;34:543-551
162. Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008;127:234-244
163. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y,Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ,Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010;12:R93
164. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study. J Rheumatol 2007;34:1459-1464
165. Chodick G, Amital H, Shalem Y, Kokia E, HeymannAD, Porath A, Shalev V. Persistence with statins and onset of rheumatoid arthritis: A population-based cohort study. PLoS Med 2010;7:e1000336
166. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010;67:1062-1067
167. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L,Zamvil SS. TheHMG-CoAreductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84
168. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608
169. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008;3:e1928
170. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009;72:1989-1993
171. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71: 1390-1395
172. Tiniakou I, Zannis VI, Boumpas D, Verginis P, Kardassis D. A8.28 Reconstituted high density lipoprotein (RHDL) modulates TH1 and TH17 immune responses and pro-inflammatory cytokine production in a murine model of rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl 1):A87
173. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nature Med 2006;12:178-180
174. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:893-900
175. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, Norata GD. Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:1832-1841
176. Sala F, Catapano AL, Norata GD. High density lipoproteins and atherosclerosis: Emerging aspects. J Ger Cardiol : JGC 2012;9:401-407